Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-L1

PD-L1

Brief Information

Name:Programmed death-ligand 1
Target Synonym:HPD-L1,Programmed Cell Death 1 Ligand 1,PDCD1L1,B7H1,PDL1,Programmed Death Ligand 1,B7-H1,B7-H,B7-H1 Antigen,CD274,B7 homolog 1,PDCD1 ligand 1,PD-L1,PDCD1LG1,CD274 Molecule,CD274 Antigen
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:103
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
SCCHO-ATP077M Human CHO/Human PD-L1 Stable Cell Line (Medium Expression) Development Service
SCCHO-ATP077H Human CHO/Human PD-L1 Stable Cell Line (High Expression) Development Service
SCCHO-ATP077L Human CHO/Human PD-L1 Stable Cell Line (Low Expression) Development Service
SCRAJ-STT075 Human Raji/Human PD-L1 Stable Cell Line Development Service
EP-133 Human PD-L1 : PD-1 [Biotinylated] Inhibitor Screening ELISA Kit
PDL-C82E8 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His,Avitag™ (MALS verified)
PDL-C82E8-structure
PDL-C82E8-sds
PDL-C52H4 Canine Canine PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PDL-C52H4-structure
PDL-C52H4-sds
PD1-H82A3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A3-structure
PD1-H82A3-sds
PD1-H52H3 Human Human PD-L1 / B7-H1 (19-134) Protein, His Tag (MALS verified)
PD1-H52H3-structure
PD1-H52H3-sds
PD1-C52H3 Canine Canine PD-L1 / B7-H1 Protein, Fc Tag
PD1-C52H3-structure
PD1-C52H3-sds
PDL-H82E4 Human Biotinylated Human PD-L1 / B7-H1 (19-134) Protein, His,Avitag™ (recommended for biopanning) (MALS verified)
PDL-H82E4-structure
PDL-H82E4-sds
PDL-R52H6 Rabbit Rabbit PD-L1 / B7-H1 Protein, His Tag
PDL-R52H6-structure
PDL-R52H6-sds
PDL-H5250 Human Human PD-L1 / B7-H1 Protein, Llama IgG2b Fc Tag, low endotoxin
PDL-H5250-structure
PDL-H5250-sds
PDL-H82F2 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PDL-H82F2-structure
PDL-H82F2-sds
PD1-M52A2 Mouse Mouse PD-L1 / B7-H1 Protein, Mouse IgG2a Fc Tag, low endotoxin
PD1-M52A2-structure
PD1-M52A2-sds
PD1-H82E5 Human Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (recommended for biopanning, MALS verified)
PD1-H82E5-structure
PD1-H82E5-sds
PD1-M82F5 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, Fc,Avitag™
PD1-M82F5-structure
PD1-M82F5-sds
PD1-M5220 Mouse Mouse PD-L1 / B7-H1 Protein, His Tag
PD1-M5220-structure
PD1-M5220-sds
PD1-M5251 Mouse Mouse PD-L1 / B7-H1 Protein, Fc Tag
PD1-M5251-structure
PD1-M5251-sds
PD1-H52A3 Human Human PD-L1 / B7-H1 Protein, Mouse IgG1 Fc Tag, low endotoxin (MALS verified)
PD1-H52A3-structure
PD1-H52A3-sds
PD1-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-C52H4-structure
PD1-C52H4-sds
PD1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag
PD1-C5253-structure
PD1-C5253-sds
PD1-H82F3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F3-structure
PD1-H82F3-sds
PD1-H5282 Human Human PD-L1 / B7-H1 Protein, Strep Tag
PD1-H5282-structure
PD1-H5282-sds
PD1-H5258 Human Human PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-H5258-structure
PD1-H5258-sds
PD1-H5229 Human Human PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-H5229-structure
PD1-H5229-sds

Part of Bioactivity data

SCCHO-ATP077M-Cell-based assay
 PD-L1 FACS

Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).

SCCHO-ATP077H-Cell-based assay
 PD-L1 FACS

Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).

PDL-C82E8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Cynomolgus PD-1, Fc Tag (Cat. No. PD1-C5254) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Cynomolgus / Rhesus macaque PD-L1, His,Avitag (Cat. No. PDL-C82E8) with an affinity constant of 6.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

PD1-M5220-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

Background

Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Sugemalimab WBP-3155; CS-1001 Approved Cstone Pharmaceuticals (Suzhou) Co Ltd 择捷美 Mainland China Carcinoma, Non-Small-Cell Lung Cstone Pharmaceuticals (Suzhou) Co Ltd 2021-12-20 Prostatic Neoplasms; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, T-Cell; Lymphoma; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Pancreatic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details
Envafolimab KN-035; ASC-22 Approved Suzhou Alphamab Co Ltd ENWEIDA, 恩维达 Mainland China Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer 3d Medicines (Sichuan) Co Ltd 2021-11-25 Sepsis; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Sarcoma; Microsatellite instability-high cancer; Neoplasms, Multiple Primary; Colonic Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Hepatitis B, Chronic; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Liver Neoplasms; HIV Infections; Shock, Septic Details
Durvalumab 28X28X9-OKV (UNII code); MEDI-4736 Approved Medimmune Llc 英飞凡, Imfinzi United States Small Cell Lung Carcinoma Astrazeneca Uk Ltd 2018-02-16 Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Gallbladder Neoplasms; Primary Myelofibrosis; Bile Duct Neoplasms; Oropharyngeal Neoplasms; Genital Neoplasms, Female; Testicular Neoplasms; Carcinoma, Squamous Cell; Pinealoma; Colorectal Neoplasms; Urologic Neoplasms; Microsatellite Instability; Nasopharyngeal Carcinoma; Vulvar Neoplasms; Sarcoma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Prostatic Neoplasms; Thyroid Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Laryngeal Diseases; Dysgerminoma; Adenocarcinoma; Carcinoma, Endometrioid; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Mouth Neoplasms; Lymphoma, T-Cell, Cutaneous; Urogenital Neoplasms; Endometrial Neoplasms; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Carcinoma; Pancreatic Neoplasms; Polycythemia Vera; Re Details
Atezolizumab RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A Approved Genentech Inc 泰圣奇, Tecentriq Mainland China Carcinoma, Non-Small-Cell Lung Roche (China) Holding Ltd 2016-05-18 Genital Neoplasms, Female; Uterine Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Neoplasms, Unknown Primary; Lung Neoplasms; Gallbladder Neoplasms; Urogenital Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Sezary Syndrome; Bile Duct Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Lymphoma, Follicular; Sarcoma; Microsatellite Instability; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Liposarcoma, Myxoid; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma; Urethral Neoplasms; Thyroid Neoplasms; Thymoma; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Lymphoma, T-Cell, Cutaneous; Penile Neoplasms; Esophageal Squamous Cell Carcinoma; Glioma; Lymphoma; Carcinoma, Renal Cell; Kidney Diseases; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Anus Neoplasms; Rectal Neoplasms Details
Avelumab PF-06834635; MSB-0010718C Approved Merck Serono Bavencio EU Carcinoma, Transitional Cell Merck Europe Bv 2017-03-23 Lymphoma; Vulvar Neoplasms; Lymphoma, Follicular; Osteosarcoma; Lymphoma, Extranodal NK-T-Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Meningeal Neoplasms; Testicular Neoplasms; Glioma; Penile Neoplasms; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Testicular Diseases; Carcinoma, Squamous Cell; Microsatellite Instability; Esophageal Squamous Cell Carcinoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Adenocarcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Meningioma; Neoplasms, Germ Cell and Embryonal; Gastrointestinal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms, Second Primary; Uterine Cervical Neoplasms; Lentivirus Infections; Triple Negative Breast Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Carcinoma, Merkel Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Anus Neoplasms; Pancreatic Neoplasms; Hodgkin Disease; Neoplasms; Gl Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Carcinoma, Non-Small-Cell Lung Details
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) Phase 1 Clinical Jiangsu Huaiyu Pharmaceutical Co Ltd Solid tumours Details
Pd-1-pik Pd-1-pik Phase 1 Clinical Huashan Hospital Affiliated To Fudan University Glioblastoma Details
IMM2505 IMM2505 Phase 1 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours Details
89Zr-KN035(Wuxi No. 4 People's Hospital) Clinical Wuxi No. 4 People Solid tumours Details
Carrizumab Phase 2 Clinical Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma Details
PM-1003 PM1003 Phase 2 Clinical Biotheus Inc Solid tumours Details
18F-BMS-986192 BMS-986192-[18F] Clinical Neoplasms Details
ADG-104 ADG-104; ADG104 Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc Neoplasms Details
JS-003 JS-003 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours Details
RG-6084 RG-6084; RO-7191863 Phase 1 Clinical F. Hoffmann-La Roche Ltd Hepatitis B Details
QL-415 QL-415 Phase 1 Clinical Neoplasms Details
QL-301 QL-301 Phase 1 Clinical Neoplasms Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details
SG12473 SG12473; SG-12473 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Solid tumours; Neoplasms Details
HB-0028 HB-0028 Phase 1 Clinical Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours Details
LP-008 LP-008 Phase 1 Clinical Lepu Biotech Co Ltd Solid tumours Details
Durvalumab/Selumetinib sulfate Phase 1 Clinical Astrazeneca Plc Neoplasms Details
TT-00420/Atezolizumab Phase 1 Clinical Gastrointestinal Neoplasms Details
Durvalumab/Gefitinib Phase 2 Clinical Medimmune Carcinoma, Non-Small-Cell Lung Details
SKB-337 SKB337; A-337; SKB-337 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
PM-1022 PM-1022 Phase 1 Clinical Biotheus Inc Neoplasms Details
Sudubrilimab HS-636 Phase 2 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Triple Negative Breast Neoplasms; Neoplasms; Primary mediastinal B cell lymphoma Details
IMM-2510 IMM-2510 Phase 1 Clinical Solid tumours Details
FH-2001 FH-2001 Phase 1 Clinical Shanghai Fosun Pharmaceutical Development Ltd Solid tumours Details
HB-0025 HB0025 Phase 1 Clinical Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours Details
TS-1905 TS-1905; LY-01019; BA-1201 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung Details
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Takeda Pharmaceutical Co Ltd, Shattuck Labs Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
GT-90008 GS-19-PLB-1C; GT-90008; GS-19 Phase 1 Clinical Solid tumours Details
CCX-559 CCX-559 Phase 1 Clinical Chemocentryx Inc Solid tumours; Neoplasms Details
Gallium [68Ga] Natan recombinant PD-L1 single domain antibody SNA-002 Phase 1 Clinical Smartnuclide Biopharma Solid tumours; Neoplasms; Contrast agents Details
Garivulimab BGB-A333 Phase 1 Clinical Beigene Ltd Neoplasms Details
Lesabelimab BC-003 Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms Details
FPT-155 CD80-Fc; FPT-155 Five Prime Therapeutics Inc Details
BJ-005 BJ-005 Phase 1 Clinical Boji Biomedical Technology (Hangzhou) Co Ltd Solid tumours Details
MT-6402 MT-6402; MT-64-6402 Molecular Templates Details
KN-052 KN-052 Phase 1 Clinical Suzhou Alphamab Co Ltd Solid tumours Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
Q-1802 Q-1802 Phase 1 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours; Gastrointestinal Diseases Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) Sichuan University Details
QLS31901 QLS-31901; QLS31901 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
Recombinant anti-PD-L1/TGF-β bispecific antibody Y101D; Y-101D Phase 1 Clinical Wuhan Yzy Biopharma Co Ltd Solid tumours Details
TJ-L14B ABL-503; TJ-L14B/ABL503; ABL503 I-Mab Biopharma Co Ltd Details
GNC-035 quadr-specific antibody(baili) GNC-035 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Metastatic breast cancer Details
PF-07257876 Details
KD-033 KD-033 Takeda Pharma Details
LBL-024 LBL024; LBL-024 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours; Neoplasms Details
QLF31907 QLF31907; QLF-31907 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
CA-170 CA-170; AUPM-170 Aurigene Details
FS-222 FS-222 F-star Beta Ltd Details
CN-202 CN-202 Phase 1 Clinical Tongrun Biomedicine (Shanghai) Co Ltd Hematologic Neoplasms; Solid tumours Details
TQB-2868 TQB-2868 Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms Details
CHECKvacc CF33-hNIS-antiPDL1 Phase 1 Clinical Imugene Ltd, City Of Hope National Medical Center Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
BPI-371153 BPI-371153 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours; Lymphoma Details
99mTc-NM-01 99mTc-NM-01 Phase 2 Clinical Nanomab Technology Ltd Carcinoma, Non-Small-Cell Lung Details
sirpiglenastat DRP-104 Dracen Pharmaceuticals Inc Details
Pacmilimab CX-072 Cytomx Therapeutics Details
PRS-344 PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 Phase 2 Clinical Pieris Pharmaceuticals Inc, Laboratoires Servier Solid tumours Details
ND-021 ND-021; NM21-1480; CS-2006; CS2006 Phase 1 Clinical Numab Therapeutics Ag, Cstone Pharmaceuticals Solid tumours; Neoplasms Details
ATG-101 ATG-101 Phase 1 Clinical Antengene Corporation Co Ltd Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) LP-002 Phase 2 Clinical Taizhou Houde Aoke Technology Co Ltd Solid tumours; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma Details
Simridarlimab IBI-322; IBI322 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms; Solid tumours; Neoplasms; Lymphoma, T-Cell; Leukemia, Myeloid, Acute Details
BMS-986189 BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 Bristol-Myers Squibb Company Details
89Zr-durvalumab Radboud University Nijmegen Details
GS-4224 GS-4224 Gilead Sciences Inc Details
Opucolimab HLX-20 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Neoplasms Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) The Second Hospital Of Nanjing Medical University Details
MCLA-145 MCLA-145 Incyte Corp, Merus Details
LOR-S03 CDX-527 Celldex Therapeutics Details
Lodapolimab LY-3300054 Eli Lilly And Company Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours Details
Davoceticept ALPN-202 Alpine Immune Sciences Details
FAZ-053 FAZ-053; LAE-005; LAE005 Phase 2 Clinical Novartis Pharma Ag Solid tumours; Triple Negative Breast Neoplasms Details
ABSK-043 ABSK043 Phase 1 Clinical Solid tumours; Neoplasms Details
TQB-2858 TQB-2858 Phase 2 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Pancreatic Neoplasms; Neoplasms; Nasopharyngeal Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
BS-006 BS-006 Phase 1 Clinical Wuhan Binhui Biotechnology Co Ltd Solid tumours; Uterine Cervical Neoplasms Details
GR-1405 GR-1405 Phase 1 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Lymphoma Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Sarcoma; Gallbladder Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
PM-8001 6MW3111; PM-8001 Phase 2 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BR-102 BR102 Phase 1 Clinical BioRay Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
HLX-301 HLX-301 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Emdifen Phase 1 Clinical Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences Solid tumours Details
ASC-61 ASC-61 Phase 1 Clinical Ascletis Pharma Inc Solid tumours; Neoplasms Details
RC-98 RC-98; RC98 Phase 2 Clinical RemeGen Co Ltd Solid tumours; Stomach Neoplasms Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis Details
Cosibelimab CK-301; TG-1501 Phase 3 Clinical Dana-Farber Cancer Institute Lymphoma; Carcinoma, Non-Small-Cell Lung Details
BMS-936559 MDX-1105; BMS-936559 Phase 3 Clinical Bristol-Myers Squibb Company Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Liver Neoplasms; Rectal Neoplasms; Sepsis; Hodgkin Disease; Colonic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
ACT-001 ACT-001 Phase 2 Clinical Accendatech Glioblastoma; Ganglioglioma; Optic Neuritis; Central Nervous System Neoplasms; Neuromyelitis Optica; Breast Neoplasms; Glioma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
6MW-3211 6MW3211; 6MW-3211 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Carcinoma, Renal Cell; Neoplasms; Myelodysplastic Syndromes; Lymphoma; Lung Neoplasms; Leukemia, Myeloid, Acute Details
SHS-006(Nanjing Sanhome Pharmaceutical) SHS-006; SH-006; SH006 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours Details
TST-005 TST-005; TST005 Phase 1 Clinical Mabspace Biosciences Co Ltd Solid tumours; Neoplasms; Papillomavirus Infections Details
SHS-009 SHS-009; SH009; SH-009 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Neoplasms Details
Ori-Bs-001 Ori-Bs-001 Phase 1 Clinical OriginCell Therapeutics Co Ltd Solid tumours Details
HB-0036 HB-0036 Phase 2 Clinical Huabo Biopharm Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Reozalimab IBI-318; LY-3434172; LY3434172 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
PM-8002 PM8002; PM-8002 Phase 2 Clinical Biotheus Inc Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Mesothelioma; Carcinoma, Hepatocellular Details
BAT-7104 BAT-7104 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Neoplasms Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
Erfonrilimab KN-046; KN046 Phase 3 Clinical Jiangsu Alphamab Biopharmaceuticals Co Ltd, Suzhou Alphamab Co Ltd Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Pancreatic Ductal; Lymphoma; Thymoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Retlirafusp alfa SHR-1701 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
INCB-086550 INCB-086550; INCB-86550 Phase 2 Clinical Incyte Corp Solid tumours; Carcinoma, Renal Cell; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
CYTO-102 CYTO-NK-102; CYTO-102 Phase 1 Clinical CytoImmune Therapeutics Inc Carcinoma, Non-Small-Cell Lung Details
IMC-001 IMC-001; STI-3031; STI-A1015 Phase 2 Clinical Sorrento Therapeutics Lymphoma, T-Cell, Peripheral; Solid tumours; Biliary Tract Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Neoplasm Metastasis Details
Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) Phase 1 Clinical Sichuan University Serositis; Ascites Details
TQB-2450 APL-502; CBT-502; TQ-B2450 Phase 3 Clinical Cbt Carcinoma, Squamous Cell; Primary mediastinal B cell lymphoma; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Stroke; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Esophageal Diseases; Digestive System Diseases; Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Biliary Tract Neoplasms; Genital Diseases, Female; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Esophageal Neoplasms; Lymphoma, B-Cell; Gastrointestinal Diseases; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Neoplasms, Squamous Cell; Digestive System Neoplasms Details
SGN-PDL1V SGN-PDL1V Phase 1 Clinical Seagen Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Emfizatamab GNC-038 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin Details
Acasunlimab PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 Phase 2 Clinical Genmab, Biontech Se Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Betifisolimab MSB-2311 Phase 1 Clinical Mabspace Biosciences Co Ltd Solid tumours Details
AN-4005 AN-4005 Phase 1 Clinical Hangzhou Adlai Nortye Biomedical Technology Co Ltd Solid tumours; Neoplasms; Lymphoma Details
MVR-C5252 C-5252; MVR-C5252 Phase 1 Clinical Immvira Co Ltd Solid tumours; Glioblastoma; Ganglioglioma; Brain Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message